Willingness to Pay for Different Severity Levels in Sweden: An Analysis of TLV Decisions (2014-2022)

Authors: Viollet J, O'Leary E, Camacho Gonzalez C, Lauppe R, Oldsberg L Affiliation: Quantify Research, Stockholm, Sweden

Objectives

- The Swedish Dental and Pharmaceutical Benefits Agency (TLV) decides on the reimbursement of outpatient drugs
- TLV's willingness to pay (WTP) is based on the severity level of the indication
- Objective: to determine which WTP thresholds TLV followed in practice and whether they had evolved over time

ICERs in decisions had different reimbursement outcomes

HIA228

Summary of assessments included in the analysis by severity level reported

	Low	Medium	High	Very high
Full reimbursement	0%	26%	33%	39%
Limited reimbursement (subpopulation)	14%	56%	43%	29%
Reimbursement limited to indication assessed	0%	13%	0%	20%
No reimbursement	86%	5%	23%	12%
Total number of ICERs considered	7	39	30	51

Methods

- Data was collected from all decisions made between January 2014 and June 2022 that include a single base case ICER (not a range) by TLV
- Variables extracted:
 - Product-specific information: product name, substance name, manufacturer name, indication
 - Severity: when a range of severity levels was available, the lowest one was selected
 - TLV's ICER and its patient population
 - Whether TLV considered the ICER to be above what is reasonable (if yes, the decision was excluded from the analysis)
 - Decision date
 - Use of confidential price in the evaluation (for product only) Reimbursement outcome for the product

Note: 7 decisions that included ICERs did not report severity levels

TLV's base case ICERs and decisions point to severity WTP thresholds around 200,000 SEK for low severity, 600,000 SEK for medium, 750,000 SEK for high and 1,000,000 SEK for very high



- Population covered by reimbursement
- The reimbursement outcome for the ICER population (full reimbursement, reimbursement for subpopulation, limited to indication assessed or not reimbursed) was derived from the population considered in the ICER calculation and the population reimbursed after the assessment

Results

- 101 decisions collected for reimbursement status
 - 31% general reimbursement
 - 55% limited reimbursement
 - 14% declined
- 137 single base case ICERs calculated by TLV extracted (some decisions include more than 1 ICER)
- Severity was a factor leading to different WTP levels
- For the same severity, no large difference in WTP between

Average WTP by severity level has been stable since 2016

Rolling average of ICERs for assessments resulting in reimbursement (any type) by severity level



decisions with different reimbursement outcomes for the ICER population

Conclusions

- WTP thresholds applied in practice are largely aligned with the unofficial, but often referred to WTP thresholds according to severity level (low: 250,000 SEK, medium: 500,000 SEK, high: 750,000 SEK and very high: 1,000,000 SEK)
- These WTP thresholds can be used for predicting success of submissions to TLV



Presented at the Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 6 – 9 November 2022, Vienna, Austria.